Wells Fargo
SONN

Wells Fargo’s Sonnet BioTherapeutics SONN Stock Holding History

Wells Fargo’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$41 – 7423
2024
Q1 		$41 Hold
3
– – ﹤0.01% 6882
2023
Q4 		$37 Buy
3
+2
+200% +$27 ﹤0.01% 7008
2023
Q3 		$32 Hold
1
– – ﹤0.01% 7042
2023
Q2 		$92 Buy
+1
New +$71 ﹤0.01% 6890
2023
Q1 		– Hold
0
– – – 7354
2022
Q4 		– Hold
0
– – – 6964
2022
Q3 		– Hold
0
– – – 7301
2022
Q2 		– Hold
0
– – – 7430
2022
Q1 		– Hold
0
– – – 7751
2021
Q4 		– Hold
0
– – – 7761
2021
Q3 		– Hold
0
– – – 7469
2021
Q2 		– Hold
0
– – – 7391
2021
Q1 		– Hold
0
– – – 7330
2020
Q4 		– Hold
0
– – – 6973
2020
Q3 		– Hold
0
– – – 6853
2020
Q2 		– Hold
0
– – – 6770
2020
Q1 		– Hold
0
– – – 6742
2016
Q4 		– Hold
0
– – – 6433
2016
Q3 		– Hold
0
– – – 6326
2016
Q2 		– Hold
0
– – – 6306

Other funds holding SONN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo's SONN Position: Q2 2024 in Review

Wells Fargo sold out of Sonnet BioTherapeutics (SONN) in Q2 2024, closing a stake of 3 shares — an estimated $41 sold.

Wells Fargo first reported a position in SONN in Q2 2023 and held it in 4 quarters. The position peaked at $92 in Q2 2023. 10 funds tracked by Wall St. Rank hold SONN as of Q2 2024.

  • Wells Fargo reported no remaining Sonnet BioTherapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 3 Sonnet BioTherapeutics shares in Q2 2024, an estimated $41.
  • Wells Fargo first reported a position in Sonnet BioTherapeutics in Q2 2023 and held it in 4 quarters.
  • Wells Fargo's Sonnet BioTherapeutics position peaked at $92 in Q2 2023.
  • 10 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.